Skip to Main Content

Author Details

George Au-Yeung
The University of Melbourne
2012
27
12
PMIDPaper TitleJournal TitlePublished Year
36730890<i>CCNE1</i> Amplification as a Therapeutic Target.J Clin Oncol2023
38093958Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis.Front Endocrinol (Lausanne)2023
36999648BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme.Histopathology2023
36730890<i>CCNE1</i> Amplification as a Therapeutic Target.J Clin Oncol2023
36849657Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.Nat Genet2023
38093958Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis.Front Endocrinol (Lausanne)2023
36999648BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme.Histopathology2023
36849657Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.Nat Genet2023
35321889Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients.Int J Gynecol Cancer2022
35383113Characterization of the treatment-naive immune microenvironment in melanoma with <i>BRAF</i> mutation.J Immunother Cancer2022
35550554Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.J Immunother Cancer2022
35780474mRNA vaccines: a transformative technology with applications beyond COVID-19.Med J Aust2022
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
35321889Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients.Int J Gynecol Cancer2022
35550554Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.J Immunother Cancer2022
35383113Characterization of the treatment-naive immune microenvironment in melanoma with <i>BRAF</i> mutation.J Immunother Cancer2022
35780474mRNA vaccines: a transformative technology with applications beyond COVID-19.Med J Aust2022
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
32376722Efficacy of immune checkpoint inhibitors for in-transit melanoma.J Immunother Cancer2020
32381362Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.Gynecol Oncol2020
32376722Efficacy of immune checkpoint inhibitors for in-transit melanoma.J Immunother Cancer2020
32114479i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol.BMJ Open2020
32338306FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.Eur J Nucl Med Mol Imaging2020
31707280A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies.Eur J Cancer2020
32917727Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell Cancer.Cancer Res2020
33060145Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma.J Immunother Cancer2020
31707280A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies.Eur J Cancer2020
33060145Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma.J Immunother Cancer2020
32917727Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell Cancer.Cancer Res2020
32338306FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.Eur J Nucl Med Mol Imaging2020
32114479i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol.BMJ Open2020
32381362Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.Gynecol Oncol2020
3020901519q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.Gynecol Oncol2018
3020901519q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.Gynecol Oncol2018
27663592Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.Clin Cancer Res2017
28646021<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.Cancer Res2017
27663592Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.Clin Cancer Res2017
28646021<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.Cancer Res2017
26017449Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
26017449Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
26503049Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
26503049Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.Nature2015
24680586Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).Gynecol Oncol2014
24680586Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).Gynecol Oncol2014
23374561Radiation with cisplatin or carboplatin for locally advanced cervix cancer: the experience of a tertiary cancer centre.J Med Imaging Radiat Oncol2013
24218601Synthetic lethality between CCNE1 amplification and loss of BRCA1.Proc Natl Acad Sci U S A2013
24004674Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.Clin Cancer Res2013
23374561Radiation with cisplatin or carboplatin for locally advanced cervix cancer: the experience of a tertiary cancer centre.J Med Imaging Radiat Oncol2013
24218601Synthetic lethality between CCNE1 amplification and loss of BRCA1.Proc Natl Acad Sci U S A2013
24004674Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.Clin Cancer Res2013
  • 1 - 50 of 54

Recommended Authors

Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 32
Stephen Welch
Victoria Hospital
Career Start Year 2007
Number of shared co-authors 0
Julia A Beaver
Center for Drug Evaluation and Research
Career Start Year 2007
Number of shared co-authors 0
Liz-Anne Lewsley
CRUK Clinical Trials Unit, University of Glasgow
Career Start Year 2006
Number of shared co-authors 24
Rodrigo Dienstmann
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
Career Start Year 2006
Number of shared co-authors 0
Susana Banerjee
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Career Start Year 2005
Number of shared co-authors 28
Shubham Pant
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 0
Aditya Bardia
Massachusetts General Hospital Cancer Center
Career Start Year 2004
Number of shared co-authors 1
Pavlos Msaouel
The University of Texas MD Anderson Cancer Center
Career Start Year 2004
Number of shared co-authors 0
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 1
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 0
Maria Del Pilar Estevez Diz
Instituto do Cancer do Estado de Sao Paulo and Universidade de Sao Paulo
Career Start Year 2002
Number of shared co-authors 0
Sven Mahner
University Hospital
Career Start Year 2002
Number of shared co-authors 24
Jes??s Garc??a-Donas
HM Hospitales-Centro Integral Oncologico Clara Campal
Career Start Year 2001
Number of shared co-authors 28
Saravut J Weroha
Mayo Clinic
Career Start Year 2001
Number of shared co-authors 11
Douglas A Levine
Perlmutter Cancer Center
Career Start Year 1999
Number of shared co-authors 33
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 1
Thomas J George
UF Health Cancer Center
Career Start Year 1998
Number of shared co-authors 0
Isabelle Ray-Coquard
University Claude Bernard Lyon I
Career Start Year 1997
Number of shared co-authors 28
Iain A McNeish
Ovarian Cancer Action Research Centre, Imperial College London
Career Start Year 1996
Number of shared co-authors 29
Giuseppe Curigliano
University of Milan
Career Start Year 1996
Number of shared co-authors 2
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 1
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 0
Rosalind Glasspool
University of Glasgow
Career Start Year 1992
Number of shared co-authors 28
Ramona F Swaby
Merck & Co., Inc.
Career Start Year 1991
Number of shared co-authors 0
Anil K Sood
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 11
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 0
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 1
Stefan Aebi
University of Bern
Career Start Year 1985
Number of shared co-authors 1
Gottfried E Konecny
David Geffen School of Medicine at University of California Los Angeles
Career Start Year 1984
Number of shared co-authors 30

Collaborators

David D L Bowtell
Peter MacCallum Cancer Centre
Co-authored papers 12
Dariush Etemadmoghadam
Peter MacCallum Cancer Centre
Co-authored papers 7
Sian Fereday
Peter MacCallum Cancer Centre
Co-authored papers 6
Kathryn Alsop
Peter MacCallum Cancer Centre
Co-authored papers 6
Anna DeFazio
Westmead Hospital
Co-authored papers 6
Joy Hendley
Peter MacCallum Cancer Centre
Co-authored papers 5
Joshy George
Peter MacCallum Cancer Centre
Co-authored papers 5
Yoke-Eng Chiew
Westmead Hospital
Co-authored papers 4
Heather Thorne
Peter MacCallum Cancer Centre
Co-authored papers 4
Grant A McArthur
University of Melbourne
Co-authored papers 4
Paul Harnett
Westmead Clinical School, University of Sydney
Co-authored papers 4
Catherine J Kennedy
The Westmead Institute for Medical Research, University of Sydney
Co-authored papers 4
Nadia Traficante
Peter MacCallum Cancer Centre
Co-authored papers 3
John V Pearson
QIMR Berghofer Medical Research Institute
Co-authored papers 3
Ann-Marie Patch
QIMR Berghofer Medical Research Institute
Co-authored papers 3
Ronny Drapkin
University of Pennsylvania School of Medicine
Co-authored papers 3
Nicola Waddell
QIMR Berghofer Medical Research Institute
Co-authored papers 3
Sean M Grimmond
The University of Melbourne
Co-authored papers 3
Robert Brown
Ovarian Cancer Action Research Centre, Imperial College London
Co-authored papers 2
J Lynn Fink
The University of Queensland Diamantina Institute, The University of Queensland
Co-authored papers 2
Karin S Kassahn
Adelaide Medical School, The University of Adelaide
Co-authored papers 2
Thomas P Conrads
Women's Health Integrated Research Center, Inova Health System
Co-authored papers 2
Georgina V Long
Co-authored papers 2
Ernst Lengyel
University of Chicago
Co-authored papers 2
Huei San Leong
Peter MacCallum Cancer Centre
Co-authored papers 2
Barbara A Weir
Janssen Research and Development LLC
Co-authored papers 2
Katia Nones
QIMR Berghofer Medical Research Institute
Co-authored papers 2
Maria A Doyle
Peter MacCallum Cancer Centre
Co-authored papers 2
Euan A Stronach
Imperial College London
Co-authored papers 2
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 2
Release 1.2